This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Langer Corey J
Role of targeted therapy in non-small cell lung cancer: hype or hope?
Expert Review of Anticancer Therapy. 2003 ;3(4) :443-455
PMID: AN 2003:728613
AbstractNew cytotoxic therapies, including the taxanes, gemcitabine (Gemzar, vinorelbine (Navelbine) and irinotecan (Campto), have improved treatment outcome and expanded treatment options in advanced non-small cell lung cancer. However, despite their promise, a therapeutic plateau with response rates of 20-30% and 1-yr survival rates of 30-40% has been reached. It is doubtful if exchanging one agent for another in various combinations will lead to any significant improvement. The thrust of current research focuses on targeted therapy and its careful integration into the std. treatment paradigm. These agents include compunds targeted at growth factor receptors, angiogenesis, cyclooxygenase, farnesyl transferase and protein kinase C-a. Preclin. models have demonstrated synergy for many of these agents in combination with either chemotherapy or radiation, although clin. challenges exist. These include the identification of an optimal biol. dose, the proper integration of these agents into systemic chemotherapy regimens, and selecting the best setting in which to test the compds. [on SciFinder (R)]
Notes1 Pharmacology Fox Chase Cancer Center,Philadelphia,PA,USA. Journal 1473-7140 written in English.